Chern lee sutton biography definition
•
An overview of clinical decision support systems: benefits, risks, and strategies for success
References
Osheroff, J. et al. Improving Outcomes with Clinical Decision Support: An Implementer’s Guide. (HIMSS Publishing, ).
Sim, inom. et al. Clinical decision support systems for the practice of evidence-based medicin. J. Am. Med Inf. Assoc. Jamia.8, – ().
ArticleCAS Google Scholar
De Dombal, F. Computers, diagnoses and patients with acute abdominal pain. Arch. Emerg. Med. 9, – ().
Shortliffe, E. H. & Buchanan, B. G. A model of inexact resoning in medicine. Math. Biosci., – ().
Google Scholar
Middleton, B., Sittig, D. F. & Wright, A. Clinical decision support: a 25 year retrospective and a 25 year framtidsperspektiv. Yearb. tillsammans med. Inform.25(S 01), S–S ().
Article Google Scholar
Dias, D. Wearable health devices—vital sign monitoring, systems and technologies. ().
Berner, E. S. (Ed.). Clinical Decision Support Systems (Springer, New York, NY, ).
•
Abstract
Background
Adverse pregnancy outcomes, such as preterm birth (PTB), have been associated with elevated risk of maternal cardiovascular disease, but their effect on late midlife blood pressure (BP) and subclinical vascular measures remains understudied.
Methods and Results
We conducted a cross‐sectional analysis with multiethnic parous women enrolled in SWAN (Study of Women's Health Across the Nation) to evaluate the impact of self‐reported history of adverse pregnancy outcomes (PTB, small‐for‐gestational‐age, stillbirth), on maternal BP, mean arterial pressure, and subclinical vascular measures (carotid intima‐media thickness, plaque, and pulse wave velocity) in late midlife. We also examined whether these associations were modified by race/ethnicity. Associations were tested in linear and logistic regression models adjusting for sociodemographics, reproductive factors, cardiovascular risk factors, and medications. Women were on average aged 60 years and women reported
•
Abstract
The convergence of advances in medical science, human biology, data science, and technology has enabled the generation of new insights into the phenotype known as “diabetes.” Increased knowledge of this condition has emerged from populations around the world, illuminating the differences in how diabetes presents, its variable prevalence, and how best practice in treatment varies between populations. In parallel, focus has been placed on the development of tools for the application of precision medicine to numerous conditions. This Consensus Report presents the American Diabetes Association (ADA) Precision Medicine in Diabetes Initiative in partnership with the European Association for the Study of Diabetes (EASD), including its mission, the current state of the field, and prospects for the future. Expert opinions are presented on areas of precision diagnostics and precision therapeutics (including prevention and treatment), and key barriers to and opportunities for impleme